Blog Posts

Amidst greater market uncertainty and a severely constrained IPO environment, mergers and acquisitions (M&A) are serving as a critical “life raft” for investment, innovation and growth in America’s life sciences industry, reports Axios’ Katherine Davis in her recent article, “Biotechs search for buyers as runways end.”

In response to the Office of Management and Budget’s recent Request for Information on Deregulation, PULSE urged federal regulators to revisit the latest changes to the Hart-Scott-Rodino (HSR) premerger notification rule.

As part of PULSE’s efforts to engage policymakers around the unique and fundamental role of mergers and acquisitions (M&A) within the life sciences industry, PULSE partners made their way to Capitol Hill to emphasize how these critical partnerships are advancing new medicines to patients.

The U.S. life sciences industry is a key driver of economic growth and domestic manufacturing. American pharmaceutical manufacturers employ an estimated 291,000 employees, and for every one job in the pharmaceutical industry, four jobs are created in supporting...

As the need for more effective and accessible obesity medicines grows, mergers and acquisitions (M&A) have emerged as a key strategy for life science companies of all sizes to accelerate innovation and competition to bring new treatment options to patients.

M&A in America’s life sciences industry not only plays a critical role in bringing new breakthroughs to patients, but also strengthens state economies across the country. Life sciences M&A plays a pivotal role in fueling innovation, creating jobs and attracting long-term investment to local communities.

A new PULSE resource includes key insights from economists at Cornerstone Research on the the unique and fundamental role of mergers and acquisitions (M&A) in driving innovation across America’s biopharmaceutical industry.

With more than 80% of life sciences companies operating without a profit, external investment—including from venture capital (VC)—is often critical to bringing a new treatment or cure to market. As macroeconomic headwinds have made investors increasingly cautious about investing in early-stage companies, mergers and acquisitions (M&A) play a crucial role in sustaining innovation across the American life sciences ecosystem.

For decades, mergers and acquisitions (M&A) have fueled the development and delivery of breakthrough treatments for complex diseases with a high unmet need. A new resource from the Partnership for the U.S. Life Science Ecosystem (PULSE) spotlights this unique and...

New resources from the Partnership for the U.S. Life Science Ecosystem (PULSE) highlight the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. Life sciences M&A represents a critical pathway for companies of all...